Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
21.02. | IsomAb secures funds to advance peripheral arterial disease treatment | ||
20.02. | Everest Medicines to terminate deal with Providence for mRNA platform | ||
19.02. | FDA grants breakthrough therapy status for Otsuka's IgAN drug | ||
16.02. | Japan grants priority review for Astellas' urothelial cancer regimen | ||
15.02. | Atara submits IND application to FDA for CAR T-cell therapy | ||
14.02. | ProfoundBio secures $112m to advance ADC portfolio for cancer | ||
13.02. | Precision receives payments from TG Therapeutics for azer-cel | ||
12.02. | FDA grants orphan drug designation for Disc's PV treatment | ||
09.02. | Aizon secures funds to accelerate development pipeline | ||
08.02. | Samsung Biologics and LegoChem enter ADC development deal | ||
07.02. | NIH grants $9m for nicotine cessation drug development | ||
06.02. | Exicure and Bluejay sign hepatitis treatment development deal | ||
05.02. | Zuellig Pharma acquires Cialis and Alimta brands from Lilly | ||
02.02. | US FDA grants orphan drug status for Rznomics' HCC treatment | ||
01.02. | Sandoz launches Tyruko in Germany for treatment of adults with RRMS | ||
31.01. | US FDA grants ODD to NeoImmuneTech's NT-I7 for pancreatic cancer treatment | ||
30.01. | Oricell's OriCAR-017 application secures FDA IND clearance | ||
29.01. | EMA validates Pfizer-Astellas' bladder cancer therapy application for review | ||
26.01. | Entos opens GMP clinical manufacturing facility in US | ||
25.01. | UroGen submits new drug application to FDA for UGN-102 | ||
24.01. | BlueRock exercises option to license cell therapy candidate | ||
23.01. | ASTCT, ACCC and AACI launch initiative for CAR T therapy | ||
22.01. | Zokinvy gets Japanese approval for Progeria treatment | ||
19.01. | Kindeva Drug Delivery acquires Summit Biosciences | ||
18.01. | Eurofins Alphora completes Canadian biologics development facility |